AptaBio Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
AptaBio Therapeutics has a total shareholder equity of ₩57.5B and total debt of ₩14.5B, which brings its debt-to-equity ratio to 25.2%. Its total assets and total liabilities are ₩89.9B and ₩32.4B respectively.
Key information
25.2%
Debt to equity ratio
₩14.47b
Debt
Interest coverage ratio | n/a |
Cash | ₩50.07b |
Equity | ₩57.52b |
Total liabilities | ₩32.37b |
Total assets | ₩89.88b |
Recent financial health updates
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth
Jan 01Recent updates
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?
Feb 23Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth
Jan 01Financial Position Analysis
Short Term Liabilities: A293780's short term assets (₩55.2B) exceed its short term liabilities (₩1.1B).
Long Term Liabilities: A293780's short term assets (₩55.2B) exceed its long term liabilities (₩31.3B).
Debt to Equity History and Analysis
Debt Level: A293780 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A293780's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A293780 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A293780 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 52.4% each year.